Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: September 21, 2005
Last updated: April 6, 2012
Last verified: April 2012
The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Condition Intervention Phase
Drug: PF-00299804
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of 2 Dosing Schedules Of PF-00299804 In Patients With Advanced Malignant Solid Tumors

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Pharmacodynamics [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Efficacy [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 121
Study Start Date: October 2005
Study Completion Date: September 2010
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
open label single arm trial
Drug: PF-00299804
investigational drug by oral route (escalating doses depending on safety) administered until progression


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Malignant solid tumor for which there is no currently approved treatment
  • Adequate bone marrow, liver, cardiac, and kidney function

Exclusion Criteria:

  • Cardiac disease
  • Anticancer therapy within 4-6 weeks (depending on therapy)
  • Pregnant or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00225121

United States, California
Pfizer Investigational Site
Los Angeles, California, United States, 90095
Pfizer Investigational Site
Santa Monica, California, United States, 90404
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
Pfizer Investigational Site
Amsterdam, Netherlands, 1066 CX
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pfizer Identifier: NCT00225121     History of Changes
Obsolete Identifiers: NCT00276653, NCT00278291
Other Study ID Numbers: A7471001 
Study First Received: September 21, 2005
Last Updated: April 6, 2012
Health Authority: United States: Food and Drug Administration processed this record on October 27, 2016